- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Wet age-related macular degeneration (AMD)
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1144KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 110KB)
Brolucizumab – March 2021
Brolucizumab: Solution for intravitreal injection 19.8 mg in 0.165 mL pre-filled syringe; Beovu®
Last updated
2 July 2021